Sionna Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell SION and other ETFs, options, and stocks.

About SION

Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It engages in researching, developing and commercializing novel medicines for cystic fibrosis. 

CEO
Michael Cloonan
CEOMichael Cloonan
Employees
41
Employees41
Headquarters
Waltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded
2019
Founded2019
Employees
41
Employees41

SION Key Statistics

Market cap
1.75B
Market cap1.75B
Price-Earnings ratio
-24.47
Price-Earnings ratio-24.47
Dividend yield
Dividend yield
Average volume
310.60K
Average volume310.60K
High today
$40.97
High today$40.97
Low today
$38.52
Low today$38.52
Open price
$38.90
Open price$38.90
Volume
264.48K
Volume264.48K
52 Week high
$45.00
52 Week high$45.00
52 Week low
$7.26
52 Week low$7.26

Stock Snapshot

Sionna Therapeutics(SION) stock is priced at $39.13, giving the company a market capitalization of 1.75B. It carries a P/E multiple of -24.47.

As of 2026-01-17, Sionna Therapeutics(SION) stock has fluctuated between $38.52 and $40.97. The current price stands at $39.13, placing the stock +1.6% above today's low and -4.5% off the high.

The Sionna Therapeutics(SION)'s current trading volume is 264.48K, compared to an average daily volume of 310.6K.

In the last year, Sionna Therapeutics(SION) shares hit a 52-week high of $45.00 and a 52-week low of $7.26.

In the last year, Sionna Therapeutics(SION) shares hit a 52-week high of $45.00 and a 52-week low of $7.26.

Analyst ratings

89%

of 9 ratings
Buy
88.9%
Hold
0%
Sell
11.1%

People also own

Based on the portfolios of people who own SION. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .